Cargando…

Hepatitis C virus core protein substitutions affect the response to pegylated-interferon and ribavirin therapy

Detalles Bibliográficos
Autores principales:	Alhamlan, Fatimah S, Al-Ahdal, Mohammed N, Khalaf, Nisreen Z, Abdo, Ayman A, Sanai, Faisal, Al-Ashgar, Hamad I, Al-Qahtani, Ahmed A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4075633/ http://dx.doi.org/10.1186/1471-2164-15-S2-P5

Ejemplares similares

Genetic variability of the core protein in hepatitis C virus genotype 4 in Saudi Arabian patients and its implication on pegylated interferon and ribavirin therapy
por: Alhamlan, Fatimah S, et al.
Publicado: (2014)

Role of Single Nucleotide Polymorphisms of KIF1B Gene in HBV-Associated Viral Hepatitis
por: Al-Qahtani, Ahmed, et al.
Publicado: (2012)

Variations in DEPDC5 gene and its association with chronic hepatitis C virus infection in Saudi Arabia
por: Al-Anazi, Mashael R, et al.
Publicado: (2014)

Correlation between Genetic Variations and Serum Level of Interleukin 28B with Virus Genotypes and Disease Progression in Chronic Hepatitis C Virus Infection
por: Al-Qahtani, Ahmed, et al.
Publicado: (2015)

The epidemic dynamics of hepatitis C virus subtypes 4a and 4d in Saudi Arabia
por: Al-Qahtani, Ahmed A., et al.
Publicado: (2017)

Association between HLA Variations and Chronic Hepatitis B Virus Infection in Saudi Arabian Patients
por: Al-Qahtani, Ahmed A., et al.
Publicado: (2014)

IL28B polymorphisms predict the virological response to standard therapy in patients with chronic hepatitis C virus genotype 4 infection
por: Abdo, Ayman A., et al.
Publicado: (2013)

The Association of Toll-Like Receptor 4 Polymorphism with Hepatitis C Virus Infection in Saudi Arabian Patients
por: Al-Qahtani, Ahmed A., et al.
Publicado: (2014)

Hepatitis C Genotype 4: Genotypic Diversity, Epidemiological Profile, and Clinical Relevance of Subtypes in Saudi Arabia
por: Al Ashgar, Hamad I, et al.
Publicado: (2013)

The Correlation Between Hepatitis B Virus Precore/Core Mutations and the Progression of Severe Liver Disease
por: Al-Qahtani, Ahmed A., et al.
Publicado: (2018)

Quasispecies of genotype 4 of hepatitis C virus genomes in Saudi patients managed with interferon alfa and ribavirin therapy
por: Al-Qahtani, Ahmed A., et al.
Publicado: (2010)

Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4
por: Al Ashgar, Hamad, et al.
Publicado: (2009)

Thyroid disturbances in children treated with combined pegylated interferon-alpha and ribavirin for chronic hepatitis C
por: Rashed, Yasser K., et al.
Publicado: (2020)

Pegylated Interferon and Ribavirin Treatment for Hepatitis C Virus Infection
por: Kagawa, Tatehiro, et al.
Publicado: (2010)

Pegylated Interferon and Ribavirin in the Retreatment of Chronic Hepatitis C in Korea
por: Cho, Hyun Chin, et al.
Publicado: (2013)

Individualized treatment of chronic hepatitis C with pegylated interferon and ribavirin
por: Carvalho-Filho, Roberto J, et al.
Publicado: (2010)

Effect of Interferon Treatment on Hearing of Patients with Chronic Hepatitis C
por: Hagr, Abdulrahman, et al.
Publicado: (2011)

Hepatitis B virus (HBV) X gene mutations and their association with liver disease progression in HBV-infected patients
por: Al-Qahtani, Ahmed A., et al.
Publicado: (2017)

Consensus Interferon Plus Ribavirin for Hepatitis C Genotype 3 Patients Previously Treated With Pegylated Interferon Plus Ribavirin
por: Abbas, Zaigham, et al.
Publicado: (2013)

Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
por: Gonçales, Fernando L, et al.
Publicado: (2010)

Thrombocytopenia in pegylated interferon and ribavirin combination therapy for chronic hepatitis C
por: Aizawa, Nobuhiro, et al.
Publicado: (2013)

Genetic variations of NOD2 and MD2 genes in hepatitis B virus infection
por: Al-Anazi, Mashael R., et al.
Publicado: (2019)

Organizing Pneumonia Associated with Pegylated Interferon α and Ribavirin Therapy
por: Chopra, Amit, et al.
Publicado: (2015)

Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients
por: Akram, Madiha, et al.
Publicado: (2011)

Association of Toll-Like Receptor 3 Single-Nucleotide Polymorphisms and Hepatitis C Virus Infection
por: Al-Anazi, Mashael R., et al.
Publicado: (2017)

Retreatment of Patients Nonresponsive to Pegylated Interferon and Ribavirin with Daily High-Dose Consensus Interferon
por: Meyer, Douglas F., et al.
Publicado: (2010)

Subcutaneous Sarcoidosis during Pegylated Interferon Alfa and Ribavirin Treatment for Chronic Hepatitis C
por: Rodríguez-Lojo, R., et al.
Publicado: (2010)

Cryptococcal meningitis in a patient with chronic hepatitis C treated with pegylated-interferon and ribavirin
por: Lee, Tae-Hee, et al.
Publicado: (2014)

Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response
por: Chak, Eric, et al.
Publicado: (2010)

Successful treatment of HCV/HBV/HDV-coinfection with pegylated interferon and ribavirin
por: Hartl, Janine, et al.
Publicado: (2012)

HBsAg clearance in chronic hepatitis B patients with add-on pegylated interferon alfa-2a to ongoing tenofovir treatment: A randomized controlled study
por: Al Ashgar, Hamad, et al.
Publicado: (2017)

Increased Ribavirin Bioavailability Associated With Telaprevir Use in Hepatitis C Patients Treated With PEGylated -Interferon/Ribavirin/Telaprevir Triple Therapy
por: Pradat, Pierre, et al.
Publicado: (2015)

Transcriptional Analysis of TP53 Gene in Chronic Hepatitis C Patients Treated with Sofosbuvir, Daclatasvir, Pegylated Interferon, and Ribavirin
por: Chudhary, Hafiza Rida Farooq, et al.
Publicado: (2023)

Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin
por: Asselah, Tarik, et al.
Publicado: (2010)

Cutaneous Sarcoidosis: An Uncommon Side Effect of Pegylated Interferon and Ribavirin Use for Chronic Hepatitis C
por: Martins, Elson Vidal, et al.
Publicado: (2009)

Expectoration of Large Bronchial Casts Secondary to the Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin
por: de Araújo, Evaldo Stanislau Affonso, et al.
Publicado: (2010)

Epidemiology of Viral Hepatitis in Saudi Arabia: Are We Off the Hook?
por: Abdo, Ayman A., et al.
Publicado: (2012)

Association between IL-37 gene polymorphisms and risk of HBV-related liver disease in a Saudi Arabian population
por: Al-Anazi, Mashael R., et al.
Publicado: (2019)

Cutaneous side effects of combination therapy of pegylated interferon 2α and ribavirin
por: Raducan, Anca, et al.
Publicado: (2014)

Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C
por: Karino, Y, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_8ql4fie4hh996skej9s8j9jhr5